CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - UNAUDITED - USD ($) $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2020		6,123,432
Balance, beginning of period at Dec. 31, 2020	$ 24,269	$ 1	$ 64,017	$ (39,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	16,059			16,059
Valuation of private warrants	(30,839)		(30,839)
Recapitalization transaction (in shares)		4,759,911
Recapitalization transaction	16,148		16,148
Issuance of common stock as compensation (in shares)		1,317,035
Issuance of common stock as compensation	2,323		2,323
Share-based compensation expense	811		811
Balance, end of period (in shares) at Mar. 31, 2021		12,200,378
Balance, end of period at Mar. 31, 2021	28,771	$ 1	52,460	(23,690)
Balance, beginning of period (in shares) at Dec. 31, 2020		6,123,432
Balance, beginning of period at Dec. 31, 2020	24,269	$ 1	64,017	(39,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	18,393
Balance, end of period (in shares) at Sep. 30, 2021		12,206,378
Balance, end of period at Sep. 30, 2021	35,956	$ 1	57,311	(21,356)
Balance, beginning of period (in shares) at Mar. 31, 2021		12,200,378
Balance, beginning of period at Mar. 31, 2021	28,771	$ 1	52,460	(23,690)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(4,790)			(4,790)
Share-based compensation expense	2,389		2,389
Balance, end of period (in shares) at Jun. 30, 2021		12,200,378
Balance, end of period at Jun. 30, 2021	26,370	$ 1	54,849	(28,480)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	7,124			7,124
Issuance of common stock as compensation (in shares)		6,000
Issuance of common stock as compensation	2,462		2,462
Balance, end of period (in shares) at Sep. 30, 2021		12,206,378
Balance, end of period at Sep. 30, 2021	35,956	$ 1	57,311	(21,356)
Balance, beginning of period (in shares) at Dec. 31, 2021		12,193,378
Balance, beginning of period at Dec. 31, 2021	37,981	$ 1	60,686	(22,706)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,964			3,964
Share-based compensation expense (in shares)		52,569
Share-based compensation expense	2,919		2,919
Conversion of private warrants to public warrants	725		725
Tax paid on behalf of employees related to net settlement of share-based awards	(225)		(225)
Balance, end of period (in shares) at Mar. 31, 2022		12,245,947
Balance, end of period at Mar. 31, 2022	45,364	$ 1	64,105	(18,742)
Balance, beginning of period (in shares) at Dec. 31, 2021		12,193,378
Balance, beginning of period at Dec. 31, 2021	37,981	$ 1	60,686	(22,706)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,406
Balance, end of period (in shares) at Sep. 30, 2022		12,238,447
Balance, end of period at Sep. 30, 2022	50,602	$ 1	69,901	(19,300)
Balance, beginning of period (in shares) at Mar. 31, 2022		12,245,947
Balance, beginning of period at Mar. 31, 2022	45,364	$ 1	64,105	(18,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	4,362			4,362
Share-based compensation expense (in shares)		(7,000)
Share-based compensation expense	3,053		3,053
Balance, end of period (in shares) at Jun. 30, 2022		12,238,947
Balance, end of period at Jun. 30, 2022	52,779	$ 1	67,158	(14,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(4,920)			(4,920)
Issuance of common stock as compensation (in shares)		6,000
Issuance of common stock as compensation	37		37
Share-based compensation expense (in shares)		(6,500)
Share-based compensation expense	2,706		2,706
Balance, end of period (in shares) at Sep. 30, 2022		12,238,447
Balance, end of period at Sep. 30, 2022	$ 50,602	$ 1	$ 69,901	$ (19,300)